Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 14/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5198303 | 0.90 | TGFBR1 (0.40) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5198402 | 0.85 | TGFBR1 (0.43) | TGFBR1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL5199690 | 0.84 | TGFBR1 (0.43) | TGFBR1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL5199536 | 0.83 | TGFBR1 (0.38) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5199509 | 0.83 | TGFBR1 (0.38) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5198453 | 0.82 | TGFBR1 (0.39) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5199982 | 0.82 | TGFBR1 (0.39) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5198088 | 0.81 | TGFBR1 (0.38) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5198246 | 0.81 | TGFBR1 (0.39) | TGFBR1TGFBR2GABRA1GABRG2GABRB3 | |
| SCHEMBL5199237 | 0.81 | TGFBR1 (0.39) | TGFBR1GABRA1GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | SANKYO COMPANY, LIMITED (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1798229-A1 | SUBSTITUTED BIPHENYL DERIVATIVE | Sankyo Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275968-A1 | Substituted Biphenyl Derivative | COL2A1, COL1A1, FGFR3 | TGFBR1 40/4885TGFBR2 51/4885GABRA1 425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.